Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAGE-targeted DNA aptamer
- Development stage
- Preclinical
- Lead developer
- Kurume University
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Subcutaneous
01
Overview
The RAGE-targeted DNA aptamer (also known as RAGE-aptamer or RAGE-Apt) is a high-affinity single-stranded DNA oligonucleotide aptamer designed to target the Receptor for Advanced Glycation Endproducts (RAGE), specifically binding to its V1 domain. Developed by researchers at Kurume University School of Medicine, this aptamer blocks the interaction of RAGE with its pathological ligands, such as advanced glycation end products (AGEs), cell-free DNA (cfDNA), and aldosterone-induced Nε-(carboxymethyl)lysine (Nε-CML). By inhibiting the AGE-RAGE axis and downstream inflammatory and fibrotic signaling pathways (including NF-κB activation), the RAGE-targeted DNA aptamer has demonstrated therapeutic potential in preclinical models of diabetic nephropathy, hypertensive nephropathy, lupus nephritis, and malignant melanoma.
- Other names
- RAGE-AptRAGE-DNA-aptamerRAGE-aptamer
02
Targets
AGER (RAGE)
Beyond the preview
Go deeper on RAGE-targeted DNA aptamer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAGE-targeted DNA aptamer.